TopoTarget A/S' positive results from the BELIEF pivotal trial with belinostat could mean upside for U.S. partner Spectrum Pharmaceuticals Inc., if the histone deacetylase (HDAC) inhibitor is approved for peripheral T-cell lymphoma, but the latest outcome with belinostat is "not really a game changer for this drug," said Decision Resources analyst Lisa Murch.
LONDON – Advanced Accelerator Applications SA has set itself the challenge of servicing 42 centers across the U.S. and Europe, in a 200-patient Phase III trial of Lutathera, a radiolabeled peptide that has a shelf life of only 72 hours.
BILBAO, Spain – Visitors to the opening day of BioSpain 2012 last week had to pass through airport-style security in the foyer of the Bilbao Exhibition Center (BEC).
• Aprea AB, of Stockholm, Sweden, reported positive data from a Phase I/II study with investigational drug APR-246. In the trial, escalating doses of APR-246 were administered as a monotherapy to 22 patients with advanced blood or prostate cancer for up to four consecutive days. Dose-limiting toxicity was shown at plasma levels well above predicted therapeutic plasma levels.
LONDON – Wellington Partners announced the first closing of its fourth life science fund at €70 million (US$90.8 million), putting the firm well on to the way to its final target of €120 million and of achieving a significant increase over its third life science fund, which raised €78 million.
LONDON – Vasopharm GmbH announced that the Phase IIa trial of its nitric oxide inhibitor VAS203 not only cleared all the safety, tolerability and pharmacokinetic hurdles, but also led to "substantially improved" neurological recovery at six months in traumatic brain injury (TBI) patients.
LONDON – An antibiotic compound originally described in 1953, but never developed, could hold the key to new treatments for multidrug-resistant strains of tuberculosis.
LONDON – Virttu Biologics Ltd. hired biotech veteran Steven Powell as CEO, with a brief to reshape strategy and turbo-charge efforts to commercialize oncolytic virus Seprehvir, a broad-spectrum product that has yet to reach the advanced stages of clinical development despite having been tested in more than 75 patients, in a number of solid tumors.
With positive overall survival data from a Phase II trial in hand, 4SC AG aims to move its pan-histone deacetylase inhibitor (HDAC) resminostat into a pivotal Phase III trial in second-line hepatocellular carcinoma (HCC) in the first half of next year.
RSS